
THE GENERAL ASSEMBLY OF PENNSYLVANIA

HOUSE RESOLUTION

No. 588 Session of
2019

INTRODUCED BY READSHAW, MEHAFFIE, HARKINS, MOUL, HILL-EVANS,
CALTAGIRONE AND DeLUCA, OCTOBER 23, 2019

REFERRED TO COMMITTEE ON HEALTH, OCTOBER 23, 2019

A RESOLUTION

1 Recognizing Fathom Pharma LLC for its efforts to mitigate the
2 opioid crisis and expressing support for continued innovation
3 by the pharmaceutical industry.

4 WHEREAS, Injuries and deaths attributable to the use of
5 prescription opioids and illicit opioids have reached epidemic
6 proportions in this Commonwealth and across the United States;
7 and

8 WHEREAS, In 2018, an estimated 4,491 drug overdose deaths
9 from accidental or undetermined causes were recorded in
10 Pennsylvania; and

11 WHEREAS, The Centers for Disease Control and Prevention
12 states that "opioid addiction is a major driver of drug
13 diversion"; and

14 WHEREAS, Prescription opioids are more likely to be diverted
15 or misused than other prescription medications; and

16 WHEREAS, Misuse of prescription opioids occurs among 21% to
17 29% of patients with chronic pain; and

18 WHEREAS, Fathom Pharma LLC is a biotechnology company

1 dedicated to treating pain and combating the opioid epidemic;
2 and

3 WHEREAS, Fathom Pharma's main laboratory is located in
4 Hummelstown; and

5 WHEREAS, Fathom Pharma is developing a long-acting injectable
6 pain relief (LAIPR) medication with an opioid reformulation that
7 provides continuous pain relief for 3 to 14 days among surgery
8 patients and 30 to 90 days among patients with chronic pain; and

9 WHEREAS, LAIPR may combat the opioid epidemic by reducing
10 potential misuse or abuse among patients and reducing risks to
11 others by taking pills off the streets and preventing them from
12 being lost, stolen or given away; and

13 WHEREAS, LAIPR may relieve prescription opioid dependence and
14 withdrawal by providing consistent levels of medication over an
15 established time frame within the therapeutic window; and

16 WHEREAS, Fathom Pharma is ready to begin the approval process
17 for clinical trials, which are likely to take place in our
18 Commonwealth; therefore be it

19 RESOLVED, That the House of Representatives recognize Fathom
20 Pharma LLC for its efforts to mitigate the opioid crisis; and be
21 it further

22 RESOLVED, That the House of Representatives express support
23 for Fathom Pharma LLC and other innovative pharmaceutical
24 companies involved in developing pain medications that are
25 effective treatments while being difficult to divert or misuse.